Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6
Open accessAbstract
A primer extension (toeprinting) assay was used to monitor selection by ribosomes of the first versus the second AUG codon as a function of introducing mutations on the 3' side (positions +4, +5 and +6) of the first AUG codon. Six different flanking codons starting with G (GCG, GCU, GCC, GCA, GAU and GGA) strongly augmented selection of AUG#1 when compared with matched mRNAs that had A or C instead of G in position +4. Augmentation by G in position +4 failed only when it was combined with U in position +5, as in the sequence augGUA. In contrast with the usual enhancing effect of introducing G in position +4, most mutations in position +5 had no discernible effect, as shown with the series augANA (where N = C, A, G or U) and the series augCNA. AUG codon recognition was also unaffected by mutations in position +6, as shown by testing four mRNAs that had augCCN as the start site. Thus the primary sequence context that augments the recognition of AUG start codons does not appear generally to extend beyond G in position +4. When the toeprinting assay was used with mRNAs that initiate translation at CUG instead of AUG, cugGAU was not recognized better than cugGGU, contradicting the hypothesis that initiation at non-AUG codons might be favored by A instead of G in position +5.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The effect of +4G and downstream nucleotides on translation initiation has been inconclusive.
“First, while the -3R (site 4 in the first column of Table 5) has been demonstrated repeatedly to enhance translation initiation, the effect of +4G (site 10 in Table 5), as well as nucleotides downstream, on translation initiation has been inconclusive [46,49,50,51].”
From Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines (2021) · cites this paper as [51]
The paper does not leave the effect of +4G inconclusive: the Discussion says its positive effect is generalizable, while the results report no significant effect from changes at +5 or +6 in the tests described. It notes a sequence-specific exception to the usual +4G effect, but presents that as an exception rather than an inconclusive overall finding (Discussion; Figures 4–6, page not provided in our copy). (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThere is little evidence that +4G and downstream nucleotides contribute to translation initiation.
“There is little evidence that +4G and downstream nucleotides contribute to translation initiation.”
From Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines (2021) · cites this paper as [51]
The Discussion reports little or no effect from varying nucleotides at +5 and +6, supporting that part of the claim. But it also reports a strong, generalizable contribution of G at +4 to initiator-codon recognition, contrary to the claim about +4G. (LLM, conf=0.90)
Experimental — accuracy not yet measuredThe -3R has been demonstrated repeatedly to enhance translation initiation.
“First, while the -3R (site 4 in the first column of Table 5) has been demonstrated repeatedly to enhance translation initiation, the effect of +4G (site 10 in Table 5), as well as nucleotides downstream, on translation initiation has been inconclusive [46,49,50,51].”
From Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines (2021) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 3
- Kozak,M. (1995) Adherence to the first-AUG rule when a second AUG codon follows closely upon the first. Proc. Natl Acad. Sci. USA, 92,
- Lin,F.-T., MacDougald,O.A., Diehl,A.M. and Lane,M.D. (1993) A 30-kDa alternative translation product of the CCAAT/enhancer binding protein α message: transcriptional activator lacking antimitotic activity. Proc. Natl Acad. Sci. USA, 90, 9606-9610.
- Ossipow,V., Descombes,P. and Schibler,U. (1993) CCAAT/enhancer binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc. Natl Acad. Sci. USA, 90, 8219-8223.
Cited by
Sorted by citations
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077 · see citing works
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278 · see citing works
Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
Xia, X. (2021) · Vaccines · doi:10.3390/vaccines9070734 · Cited by 201 · see citing works
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154 · see citing works
Malarkannan, S., Horng, T., Shih, P. P., Schwab, S., & Shastri, N. (1999) · Immunity · doi:10.1016/s1074-7613(00)80067-9 · Cited by 106 · see citing works
Gizard, F., Lavallée, B., DeWitte, F., & Hum, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100113200 · Cited by 52 · see citing works
- Authors
- Kozak, M.
- Affiliations
- University of Medicine and Dentistry of New Jersey (US)
- Corresponding author
- Kozak, Marilyn
- Venue
- The EMBO Journal
- Published
- 1997-05-01
- Volume
- 16
- Issue
- 9
- Pages
- 2482-2492
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1169848
- OpenAlex
- W2126177402
- Cited by
- 478
- References
- 0
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 8 · 2019: 8 · 2018: 12 · 2017: 12 · 2016: 8 · 2015: 7 · 2014: 15 · 2013: 11 · 2012: 16
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 33915, R01GM033915)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- codon context, non-AUG start codons, translation initiation
- MeSH terms
- Base Sequence, Binding Sites, Guanine, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Plasmids, RNA Caps, RNA, Messenger, Structure-Activity Relationship, Protein Biosynthesis, Open Reading Frames, Codon, Initiator
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review